Evaluation of the efficacy of immunotherapy for non-resectable mucosal melanoma

Moya‐Plana, Antoine; Gómez, Ruth Gabriela Herrera; Rossoni, Caroline; Dercle, Laurent; Ammari, Samy; Girault, Isabelle; Roy, Séverine Le; Scoazec, Jean‐Yves; Vagner, Stéphan; Janot, F.; Eggermont, Alexander; Robert, Caroline

doi:10.1007/s00262-019-02351-7

Cited by 56 publications

(50 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In the current study, nivolumab monotherapy for patients with advanced MM resulted in an ORR of 30%, indicating a moderate benefit. These findings suggest that some critical tumor‐associated antigens that are yet to be identified may be expressed by MM cells …”

Section: Discussionmentioning

confidence: 96%

“…These findings suggest that some critical tumor-associated antigens that are yet to be identified may be expressed by MM cells. 43 The treatment strategies for advanced MM may change with the approval of combination therapy with nivolumab and ipilimumab for advanced melanoma. 12 The pooled analysis of 35 patients with MM who received this combination therapy revealed that the median PFS was 5.9 months and that the ORR was 37.1%.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Immune‐related adverse events correlate with improved survival in patients with advanced mucosal melanoma treated with nivolumab: A single‐center retrospective study in Japan

Otsuka

Sugihara

Mori

et al. 2020

The Journal of Dermatology

View full text Add to dashboard Cite

Immune‐related adverse events (irAE) were reported to be associated with better outcomes in various cancers treated with the immune checkpoint inhibitor nivolumab. Considering that their development depends on host immune activation, irAE may reflect antitumor response in mucosal melanoma (MM). This single‐center retrospective study including patients with advanced MM receiving nivolumab monotherapy between August 2014 and September 2018 investigated whether the development of irAE was associated with clinical efficacy. The study patients were divided into those with and without irAE, and treatment efficacy and safety were evaluated. The study cohort of 27 patients included 20 (74%), six (22%) and one (4%) patient with primary MM in the head and neck, genitourinary and anorectal regions, respectively. The irAE onset was not significantly associated with the objective response rate in patients while it was significantly associated with the disease control rate. The median progression‐free survival in patients with and without irAE was 301 and 63 days, respectively. The median overall survival (OS) in patients with and without irAE was 723 and 199 days, respectively. According to the timing of irAE onset, the OS was better in seven patients who developed irAE after 180 days than in nine patients who developed irAE within 180 days. Although 16 patients (59%) experienced any grade irAE, including three (11%) with grade 3 or more irAE, there were no treatment‐related deaths. These results indicated that the development of irAE may correlate with improved survival in patients with MM treated with nivolumab monotherapy. Further studies are necessary to confirm these findings.

show abstract

Section: Discussionmentioning

confidence: 96%

Section: Discussionmentioning

confidence: 99%

Immune‐related adverse events correlate with improved survival in patients with advanced mucosal melanoma treated with nivolumab: A single‐center retrospective study in Japan

Otsuka

Sugihara

Mori

et al. 2020

The Journal of Dermatology

View full text Add to dashboard Cite

show abstract

“…29,[34][35][36][37][38][39] Pembrolizumab was independently assessed in four studies. 26,[40][41][42] An exploratory post hoc analysis of three randomized trials (KEYNOTE-001, KEYNOTE-002, and KEYNOTE-006) enrolled almost 1600 patients with stage III or IV melanoma. 40 Similarly, Japanese patients with advanced melanoma in KEYNOTE-041 were given pembrolizumab (2 mg/kg) every 3 weeks for up to 2 years or until confirmed progression or unacceptable toxicity.…”

Section: Anti-ctla-4 Monoclonal Antibodiesmentioning

confidence: 99%

Immune checkpoint inhibitors in advanced or metastatic mucosal melanoma: a systematic review

Kan

Zhao

et al. 2020

Ther Adv Med Oncol

View full text Add to dashboard Cite

Background: Conventional cytotoxic chemotherapy offers minor benefit to patients with mucosal melanoma (MM). Although immune checkpoint inhibitors (ICIs) have become the preferred approach in patients with advanced or metastatic cutaneous melanoma, the evidence of their clinical use for MM is still limited. This systematic review aims to summarize the efficacy and safety of ICIs in advanced or metastatic MM. Methods: We searched electronic databases, conference abstracts, clinical trial registers and reference lists for relevant studies. The primary outcomes included the overall response rate (ORR), median progression-free survival (PFS), median overall survival (OS), one-year PFS rate, and one-year OS rate. Results: This review identified 13 studies assessing anti-CTLA-4 monotherapy, 22 studies assessing anti-PD-1 monotherapy, two studies assessing anti-CTLA-4 and anti-PD-1 combination therapy, one study assessing anti-PD-1 antibodies combined with axitinib, and three studies assessing anti-PD-1 antibodies combined with radiotherapy. For most patients who received ipilimumab monotherapy, the ORR ranged from 0% to 17%, the median PFS was less than 5 months, and the median OS was less than 10 months. For patients who received nivolumab or pembrolizumab monotherapy, most studies showed an ORR of more than 15% and a median OS of more than 11 months. The combined administration of anti-CTLA-4 and anti-PD-1 agents showed benefits over single-agent therapy with an ORR of more than 33.3%. In a phase Ib trial of toripalimab in combination with axitinib, approximately half of patients had complete or partial responses. Three retrospective studies that investigated anti-PD-1 antibodies combined with radiotherapy showed an ORR of more than 50%, which was higher than each single modality treatment. Conclusions: Immune checkpoint inhibitors, especially anti-PD-1 monoclonal antibodies alone and in combination with anti-CTLA-4 monoclonal antibodies or other modalities, are promising treatment options for advanced or metastatic MM. However, high-level evidence is still needed to support the clinical application.

show abstract

“…Nivolumab and pembrolizumab are humanized monoclonal antibodies against PD1. In a study of 44 MM patients having metastasis including 14 patients with AM, pembrolizumab was found to be more effective than ipilimumab in prolonging the PFS [59]. Another study reported the objective response rate of 23% and 37% in MM patients receiving nivolumab alone and in combination with ipilimumab respectively [60].…”

Section: Targeted Therapiesmentioning

confidence: 99%

Anorectal Melanoma

Gupta¹,

Bansal²,

Ammar³

et al. 2021

Melanoma

View full text Add to dashboard Cite

Malignant melanoma is an aggressive disease. The anorectal region is the most common site of primary gastrointestinal malignant melanoma. Due to its low incidence, the diagnosis is often delayed. The most characteristic clinical feature of this tumor is its brown-black appearance due to the melanin pigment. However, the pigmentation may be absent in up to 20% cases. Timely diagnosis and treatment are crucial for achieving good long-term outcomes. Surgical excision remains the treatment of choice for localized disease. However, the extent of surgery has been a matter of debate. Anorectal melanoma is a highly malignant disease, and more than 50% cases have metastasis at the time of diagnosis. Targeted therapies especially immune check point inhibitors have brought about a paradigm shift in the management of cutaneous melanoma. They are being increasingly used for mucosal melanomas, and their role in anorectal melanoma is being investigated in various clinical trials.

show abstract

Evaluation of the efficacy of immunotherapy for non-resectable mucosal melanoma

Cited by 56 publications

References 33 publications

Immune‐related adverse events correlate with improved survival in patients with advanced mucosal melanoma treated with nivolumab: A single‐center retrospective study in Japan

Immune‐related adverse events correlate with improved survival in patients with advanced mucosal melanoma treated with nivolumab: A single‐center retrospective study in Japan

Immune checkpoint inhibitors in advanced or metastatic mucosal melanoma: a systematic review

Anorectal Melanoma

Contact Info

Product

Resources

About